Hillgene Biopharma

About Hillgene Biopharma

Hillgene provides comprehensive CDMO solutions for CAR-T, CAR-NK, and TCR-T therapies, supporting your journey from discovery to GMP-grade delivery. As a leading cell therapy CDMO, we have developed the core technical platform for Lentivirus and immunocytes（FDA DMF filed）, enabling the high quality delivery of CAR-T cell drug manufacturing, LVV production, and GMP-grade genetically modified K562 feeder cell production (for NK/Til expansion) , along with the regulatory support. Our professional team helps biopharma company accelerate development through flexible, scalable, and compliant processes. Whether you need more compliant and efficient K562 feeder cells(GMP Grade), or are focusing on IND applications and conducting clinical trials already preparing for commercialization, our approach ensures speed, quality, and reliability at every stage. While providing global commercial services, we are also seeking various types of partners. If you are interested in driving the development of the cell therapy industry in your country together, we welcome your inquiry.